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Abstract 
Pro-apoptotic Bcl-2 family member Bax is a crucial protein in the induction of apoptosis and its 
activation is required for this process. Here we report that Bax is a short-lived protein in 
malignant B-cells and Bax protein levels decreased rapidly when protein synthesis was blocked. 
Malignant B-cells were relatively resistant to TNF-related apoptosis inducing ligand (TRAIL)-
induced apoptosis and this correlated with low basal Bax protein levels. Furthermore, during 
treatment with TRAIL, the resistant cell lines showed prominent Bax degradation activity. This 
degradation activity was localized to mitochondrial Bax and could be prevented by truncated 
Bid (tBid), a BH3-only protein; in contrast, cytosolic Bax was relatively stable. The proteasome 
inhibitor Bortezomib is a potent drug in inducing apoptosis in vitro in malignant B-cell lines and 
primary chronic B-lymphocytic leukemic (CLL) cells. In CLL cells, Bortezomib induced Bax 
accumulation, translocation to mitochondria, conformational change, and oligomerization. 
Accumulation and stabilization of Bax protein by Bortezomib sensitized malignant B-cells to 
TRAIL-induced apoptosis. This study reveals that Bax instability confers resistance to TRAIL, 
which can be reversed by Bax stabilization with a proteasome inhibitor.  
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Introduction 
Bax is a critical element in the induction of apoptosis and having adequate levels of intracellular 
Bax protein are crucial for cells to die by apoptosis in response to death signals. During the 
apoptotic process, Bax translocates from the cytosol to the mitochondria and undergoes 
conformational changes. Insertion into the mitochondrial membrane is essential for the pro-
apoptotic activity of Bax. However, Bax protein has a shortened half-life in cancer cells due to 
greatly increased proteasome-dependent degradation activity.1 Low levels of, or absent, Bax 
protein in malignant cells are associated with significant resistance to cancer therapy. Instability 
of Bax has been found in several types of malignant cells, including Jurkat T-cell and pre-B 
acute lymphoblastic leukemia 697 cell lines,2 primary chronic lymphocytic leukemic cells 
(CLL),3 cervical cancer Hela cell line,4 and advanced human prostate cancer.1  Decrease of Bax 
protein was significantly correlated with a poor prognosis in prostate cancer1 and primary 
superficial-spreading melanoma.5  
Recently, studies have revealed that many pro-apoptotic molecules are substrates and 
targets for ubiquitin/proteasome degradation, including p53,6 tBid,7 Bax,1,4 ARTS,8 NOXA9  
and Bim.10 Alteration of the stability of these proteins through the ubiquitin/proteasome 
regulated pathway generally contributes to apoptosis resistance and poor prognosis in cancer 
cells. However, it is unclear whether the status of protein degradation by the 
ubiquitin/proteasome system could be altered by the treatment of cancer.  
 The levels of all intracellular proteins are determined by the duality of regulation: 
protein synthesis versus degradation. Basal Bax protein levels or the ratios of Bax/Bcl-2 have 
been considered to be critical factors for the sensitivity of malignant B-cells to anti-cancer 
drugs.11,12 Killing of malignant cells by induction of Bax expression commonly occurs with 
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DNA damaging agents via p53-dependent and p53-independent pathways.13,16  Proteasome 
inhibitors also have the ability to increase or maintain Bax protein levels - which are critical for 
Bax activation - when used alone or in combination with other agents.17-20 TNF-related 
apoptosis inducing ligand (TRAIL) is a promising anti-cancer agent. However, malignant B-
cells are resistant to TRAIL-induced apoptosis.21,22 We have previously found that Bax protein 
levels decline in leukemic cell lines during treatment with TRAIL.23  It is unclear whether this 
could be one of the mechanisms of the resistance of malignant B-cells to TRAIL. 
Bortezomib (PS-341, Velcade®) is a novel, first-in-class proteasome inhibitor with anti-
tumor activity against a number of hematological and non-hematological malignancies.24 In 
vitro studies showed that Bortezomib selectively inhibits proteasome-dependent degradation of 
p53,25 IκB,26 p21,27 Noxa,9,28  and TRAIL receptors DR4 and DR5.29 Proteasome inhibitors have 
been shown to be a promising approach for overcoming the resistance of tumor cells to TRAIL-
induced apoptosis.29-35  
Overexpression of Bcl-2 is one of the characteristics of malignant B-cells. However, the 
role of Bax on malignant B-cell survival and resistance to therapy has not been widely studied. 
This study has looked at Bax protein instability in malignant B-cells and the critical role of 
Bortezomib in the induction of Bax activation.  
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Materials and Methods 
Materials  
Bortezomib was provided by Millennium Pharmaceuticals (Cambridge, MA). Soluble TRAIL 
was from Biomol Ltd. (Exeter, U.K.). Annexin V-FITC kit, anti-Bax clone 6A7 and clone 3 
monoclonal antibodies were purchased from BD Biosciences (San Diego, CA). M-450 Rat anti-
Mouse IgG1 Dynalbeads was from (Dynal Biotech Ltd, Wirral, U.K.). The anti-Bax 2D2 
monoclonal antibody (clone YTH-2D2) and the recombinant caspase-8 cleaved Bid were from 
the R & D Systems (Oxon, U.K.). The anti-Bcl-2 (100), anti-Bcl-XL and anti-Bax antibodies 
were from Santa Cruz, CA. MitoTrackerTM red CMXRos was from Molecule Probes (Oregon, 
USA). RNeasy mini kit was from QIAGEN Ltd. (West Sussex, U.K.). The first-strand synthesis 
kit was purchased from UK-Invitrogen Ltd. (Paisley U.K.). The proteasome substrate III, 
Suc-Leu-Leu-Val-Tyr-AMC (Suc-LLVY-AMC) was from Alexis Biochemicals 
(Nottingham, UK). Cycloheximide (CHX), propidium iodide, 7–Amino–4–Methylcoumarin 
(AMC), the monoclonal anti-β-actin antibody, ubiquitin, anti-ubiquitin serum, protease inhibitor 
cocktail and other chemicals were from Sigma (Dorset, U.K.). 
Cell culture and clinical samples 
EBV transformed human B cell, the HRC57 cell line (is indicated as HRC in this article, 
provided by CRUK cancer cell services), and the human diffuse large B cell lymphoma cell 
lines, CRL,36 DoHH2,37 and DHL-438  and human leukemic cell line K562 were used in this 
study. Cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal 
calf serum, 25 mmol/L HEPES, 2.0 mmol/L L-glutamine at 37°C in a 5% CO2 humidified 
incubator. Peripheral blood was obtained after written informed consent from patients with CLL 
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after clinical approval. The mononuclear cells were isolated by density centrifugation over 
Ficoll.  
Apoptosis assays by flow cytometry 
Apoptosis was determined by both Annexin V and DNA content assays. The Annexin V assay 
was performed according to the protocol of the Annexin V-FITC kit. Whole cells in the binding 
buffer suspension were stained with 5 μl of Annexin V-FITC and 10 μl of propidium iodide (PI) 
for 15 minutes at the room temperature in the dark. Annexin V-FITC and PI fluorescence were 
measured on the FL1-H and FL3-H channels, respectively, by flow cytometry (Becton 
Dickinson FACScan).  Annexin V positive cells (both PI negative and positive) were defined as 
apoptotic. DNA content was measured by flow cytometry as described previously.15   
Preparation of cellular fractions  
Cells (5 ×107) were washed in Ca2+/Mg2+-free PBS and suspended in 1ml of Buffer A (250 
mmol/L sucrose, 10 mmol/L HEPES-KOH, pH 7.4, 10 mmol/L KCl, 1 mmol/L EDTA, 1 
mmol/L EGTA, 1 mmol/L DTT, 0.1 mmol/L PMSF, protease inhibitor cocktails, 20 
μmol/L cytochalasin B) and incubated for 20 minutes on ice. Cells were then broken with a 
glass Dounce homogenizer. Nuclei were separated by spinning at 790 ×g for 10 minutes at 4°C. 
The post-nuclear supernatant was further spun at 10,000 ×g for 10 minutes at 4°C to separate 
cytosol and mitochondria. The crude mitochondrial pellet was purified by passing through a 
sucrose gradient (100-300 mmol/L) cushion at 9,000 ×g for 8 minutes.39  
Proteasome activity assay 
Cytosolic or mitochondrial proteins (50 μg) were diluted to 90μl with flurogenic assay 
buffer (20 mmol/L PIPE-KOH, pH 7.4; 10 mmol/L DTT, 10% sucrose, 1.0 mmol/L EDTA, 
and 0.1% CHAPS). The reaction was initiated by the addition of 10 μl of 400 μmol/L (final 
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concentration was 40 μmol/L) fluorescent substrate, Suc-LLVY-AMC for the 
chymotrypsin-like peptidase activity of the 20S proteasome. After incubation at 37°C for 
15 minutes, the reaction was stopped by the addition of 50 μl of 1% sodium acetate 
trihydrate in 175 mmol/L acetic acid and cooling on ice. The fluorescence at 380/460 nm 
for AMC release by the proteasome cleavage was measured using a Bio-Tek SynergyTM 
HT Multi-Detection Microplate Reader (Vermont, USA). Measurements were calibrated 
against a standard linear regression curve of AMC. Proteasome activity was defined as 
μmol/L AFC release per mg protein per minute (μmol/L/min/mg protein). 
In vitro Bax degradation assay 
Mitochondria or cytosol in 5 mg/ml protein concentration were incubated in the Buffer B (250 
mmol/L sucrose, 10 mmol/L HEPES-KOH, pH 7.4, 10 mmol/L KCl, 1 mmol/L EDTA, 1 
mmol/L EGTA, 1 mmol/L DTT, 0.1 mmol/L PMSF, protease inhibitor cocktail 1:100, 50 µg/ml 
creatine phosphokinase, 10 mmol/L phosphocreatine, 2 mmol/L ATP). After the addition of 2 
µg/ml ubiquitin, the reaction mixture was incubated at 37°C for up to 3 hours in the Buffer B 
(without any detergent). Equal amount of reaction mixtures were taken out at each indicated 
time point to determine the Bax protein level by Western blotting.  
Detection of Bax conformational change and ubiquitination by immuno-precipitation 
After treatment with Bortezomib, cells were washed with PBS and lysed with the Chaps buffer 
(10 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 1% CHAPS, 1 mmol/L DTT, 0.1 mmol/L 
PMSF, 3 μg/ml aprotinin, 25 μg/ml leupeptin, and 25 μg/ml pepstain).  M-450 Rat anti-Mouse 
IgG1 Dynalbeads (20 μl) were pre-incubated with 1 μg of anti-Bax (6A7) antibody at 4°C on the 
rotor for 3 hours. The cell lysates were normalized for protein content. 500 μg of total protein in 
300 μl Chaps lysis buffer were then mixed with Bax (6A7) antibody-loaded Dynalbeads. 
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Immuno-precipitation was performed at 4°C on a rotator overnight. After rinsing 4 times with 
lysis buffer, beads were collected with a Dynal Magnetic Particle Concentrator. 
Conformationally changed Bax protein was eluted with 25 μl of loading buffer for Western 
blotting. The anti-Bax 2D2 antibody was used to detect the conformational changed Bax16 and 
the polyclonal anti-ubiquitin serum was used to determine Bax-ubiquitin conjugation. 
Immuno-fluorescence analysis of Bax translocation 
To detect Bax translocation to mitochondria, intact cells were first labeled with the 
mitochondrion-specific dye, MitoTrackerTM red CMXRos. Cells in culture medium were 
incubated with 100 nmol/L MitoTrackerTM at 37°C for 15 minutes. After washing, cells were 
fixed/permeabilized on slides. Cells were incubated with the anti-Bax clone 3 antibody, which 
only detects active Bax, at a 1:50 dilution for 1 hour and then incubated with FITC-conjugated 
anti-mouse secondary antibody (Sigma) at a 1:20 dilution. Slides were washed with PBS, air 
dried at 4°C in the dark and stained with DAPI before viewed under a Zeiss Axioskop 
fluorescence microscope (Zeiss, Germany).15,17,39  
RT-PCR 
Total RNA was extracted with the RNeasy mini kit. 1 to 5 µg RNA was used for reverse 
transcription. cDNA was synthesized with the first-strand synthesis kit and amplified with Bax 
primers (5'CCCTTTTGCTTCAGGGTTTC, and 3' primer TGTTACTGTCCAGTTCGTCC size 
151bp) or actin primers (5' GGAACGGTGAAGGTGACAG and 3' primer GGGACAA 
AAAGGGGGAAG size 338bp). PCR program was set up as below: cDNA templates denatured 
at 94°C for 2 minutes, followed by 30 cycles of denaturation at 94°C for 15 seconds, annealing 
at 56°C for 20 seconds, and an extension at 72°C for 20 seconds. Additional extension was at 
72°C for 10 minutes. The PCR product was detected in 2% agarose gel.     
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Results 
Bax is a short-lived protein in malignant B-cell lines 
The expression of the Bcl-2 family of proteins was determined in the malignant B-cell lines, 
CRL, DoHH2 and DHL-4 and compared with the EBV- transformed B-cell line, HRC. 
Malignant B-cells overexpressed Bcl-2 protein and some of them also had higher levels of Bcl-
XL. Bax protein expression was significantly lower in the malignant B-cell lines, CRL and 
DoHH2, compared with HRC cells. In agreement with a previous study,38 neither Bax nor 
Bak protein was detected in the DHL-4 cell line. Expression of Bak was not significantly altered 
in the CRL and DoHH2 cell lines in comparison with HRC (Figure 1 A). Importantly, Bax 
mRNA levels were similar in these cell lines and were not consistent with their protein levels 
(Figure 1. B). The DHL-4 cell line, which lacked Bax protein expression, had plentiful Bax 
mRNA. These results suggested that the regulation of Bax expression in these cell lines may 
occur at the post-translational level.  
The stability of Bax protein was tested in HRC, CRL, and DoHH2 cell lines after they 
were treated with cycloheximide (CHX), a protein synthesis inhibitor, and the lifespan of Bax 
protein was examined by Western blotting. Bax protein was found to be stable in the 
transformed HRC cell line but not in the malignant B-cell lines (Figure 1 C). However, CHX-
mediated Bax degradation in both CRL and DoHH2 cell lines was completely inhibited by 
pre-treatment with Bortezomib (Figure 1 D). The expression of Bak remained unchanged in 
all cell lines tested suggesting that Bak protein is relatively stable (results not shown). These 
results indicate that Bax, but not Bak, is a short-lived protein in malignant B-cells and its 
instability varies among these cells. Importantly, Bax degradation can be inhibited by 
Bortezomib.  
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TRAIL induces Bax degradation in malignant B-cell lines 
The malignant B-cells with low Bax protein expression, CRL and DoHH2, were found to be 
more resistant to TRAIL-induced apoptosis compared with the HRC cell line. DHL-4 cells, 
which had no detectable Bax protein, were highly resistant to TRAIL (Figure 2 A). The inverse 
correlation of Bax protein levels and sensitivity to TRAIL led us to examine the stability of Bax 
during treatment with TRAIL. A reduction in Bax protein was detected in the TRAIL-resistant 
CRL and DoHH2 cell lines, but not in the sensitive HRC cell line (Figure 2 B), indicating that 
Bax protein degradation occurs in malignant B-cells during TRAIL treatment in resistant cell 
lines. The expression of Bcl-2 and Bak was not significantly altered (results not shown).  These 
results demonstrate that treatment with TRAIL is associated with enhanced Bax instability in 
resistant B-cell lines.  
Proteasome inhibition promotes apoptosis in the TRAIL-resistant DHL-4 cell line 
As shown above, the DHL-4 cell line lacks Bax protein expression but not Bax mRNA (Figure 
1). Bortezomib at 20 nmol/L induced neither Bax accumulation nor apoptosis in DHL-4 cells. 
We were interested in whether proteasome inhibition could lead to an accumulation of Bax 
protein and TRAIL sensitization in the DHL-4 cell line. After DHL-4 cells were incubated with 
a high dose of Bortezomib (100 nmol/L) for 24 hours, Bax protein accumulation was observed 
by Western blotting, whereas, the Bax mRNA levels remained unchanged (Figure 3 A and B). 
DHL-4 cells were highly resistant to TRAIL-induced apoptosis, showing no apoptosis when 
cells were treated with TRAIL alone. High dose Bortezomib caused an accumulation of Bax 
protein in DHL-4 cells and sensitized these cells to TRAIL-induced apoptosis (Figure 3 C). 
These results further confirmed that the down-regulation of Bax in malignant B-cells is 
regulated at the post-translational level. Bax degradation contributes to resistance of malignant 
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B-cells to TRAIL-induced apoptosis, which can be reversed by proteasome inhibition leading to 
stabilization of Bax protein levels.  
Bax degradation occurs in the mitochondrion and can be prevented by tBid or Bortezomib
To understand why TRAIL triggers Bax degradation and whether it is associated with Bax 
translocation to mitochondria, the location of Bax degradation was tested. Mitochondria isolated 
from the human leukemic K562 cell line were used as a model because they possess an inactive 
form of the Bax protein.16,40 Cytosol was extracted from the DHL-4 cell line, which does not 
contain detectable Bax protein (Figure 1 A). The resting proteasome activity was tested in 
both cytosolic and mitochondrial fractions.  Proteasome activity was found to be mainly 
located in the cytosol. Interestingly, the DHL-4 cytosol had greater proteasome activity 
than K562 cytosol (Figure 4 A1). Bortezomib significantly inhibited proteasome activity in 
both DHL-4 and K562 cytosol (Figure 4 A2). Mitochondrial Bax degradation occurred 
when K562 mitochondria were incubated with K562 cytosol in the presence of ubiquitin and 
it was prevented by tBid. Interestingly, Bax protein degradation was not observed in the K562 
cytosol (Figure 4 B). The interaction of tBid with Bax at the mitochondrial level is a critical 
intermediate step in TRAIL-induced apoptosis in type II cells.41 The effect of tBid in Bax 
degradation was tested at the mitochondrial level. Mitochondrial Bax protein was stable when 
the K562 mitochondria were incubated in the degradation buffer containing ubiquitin for 
3 hours, indicating that cytosol is required for the degradation. Similarly, Bax was also 
relatively stable when the K562 mitochondria were incubated with K562 cytosol without 
ubiquitin (Figure 4 C). When the K562 mitochondria were incubated in the DHL-4 cytosol in 
the absence of ubiquitin, the mitochondrial Bax protein disappeared within 30 minutes, 
indicating that the mitochondrial Bax is susceptible to the degradation system present in the 
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DHL-4 cytosol, probably due to the higher proteasome activity in the DHL-4 cytosol. Bax 
degradation was prevented in the presence of tBid (Figure 4 D). To test whether the 
mitochondrial Bax degradation is proteasome-dependent, the DHL-4 cells were treated 
with 100 nM Bortezomib for 24 hours. Cytosol was then extracted from these cells and 
incubated with K562 mitochondria for 5 hours. Bax degradation was diminished by 
Bortezomib (Figure 4 E). These results indicate that Bax degradation occurs at the 
mitochondrial level and tBid prevents Bax degradation, probably by promoting stable Bax 
membrane insertion. TRAIL is known to induce Bax translocation to the mitochondria42 and this 
was thought to be an essential event in the induction of apoptosis by Bax. However, our data 
implies that Bax degradation may be active even after translocation following TRAIL 
stimulation.  
Stablizing Bax by proteasome inhibition contributes to Bortezomib-induced apoptosis in 
primary malignant B-cells  
It was determined whether the proteasome inhibitor Bortezomib could induce apoptosis and Bax 
accumulation in primary malignant B-cells. The sensitivity of CLL cells to Bortezomib-induced 
apoptosis and Bax accumulation was determined in fresh cells from 10 patients. Susceptibility 
to Bortezomib-induced apoptosis was universal, with no significant differences between cases 
(Figure 5 A), although Bax protein levels varied and different Bax degradation activities were 
shown amongst these samples – 5 cases showed Bax degradation, 3 were negative and 2 were 
not tested (Agrawal et al, accompanying paper). This suggests that the differential Bax protein 
levels and Bax degradation activity were not sufficient to affect the sensitivity of CLL cells to 
Bortezomib-induced apoptosis. Bortezomib induced Bax accumulation was observed in most 
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of CLL cases tested, although the degrees of accumulation varied among these samples 
(Figure 5 B).  
 A dose-dependent Bax protein accumulation and oligomerization (dimer and trimer) 
were observed in Bortezomib-treated CLL cells (Figure 5. C, the top panel). The accumulation 
of both p18 and p21 Bax was seen after the treatment with Bortezomib (Figure 5. C, the second 
panel). Bax activation was initially determined by a conformational change in Bax. It was 
shown that Bortezomib-induced Bax conformational change was also dose-dependent (Figure 5.  
C. the third panel). Bortezomib-induced Bax activation was also confirmed by Bax translocation 
to mitochondria. After treatment with Bortezomib, the active Bax protein (green color) merged 
with the red mitochondria, becoming yellow (Figure 5. D). These results show that Bortezomib 
induces Bax protein accumulation, a change in its conformation, translocation to mitochondria 
and an oligomerization. We have previously shown that Bax accumulation is sufficient to trigger 
its activation.16,40 It was also observed that Bortezomib caused NOXA accumulation in CLL 
cells (data not shown).  
 Next, the effect of Bortezomib on accumulation of ubiquitinated proteins and Bax-
ubiquitin conjugation was investigated. An accumulation of poly-ubiquitinated proteins was 
detected when CLL cells were treated with Bortezomib (Figure 6 A). Immuno-precipitation 
experiments showed that active Bax can be recognized by, and conjugated with, ubiquitin when 
proteasome-dependent degradation was blocked by Bortezomib. However, Bax-ubiquitin 
conjugation was also detected in the control CLL cells, but to a lesser extent compared with 
treated CLL cells (Figure 6 B). We therefore propose that Bax degradation in CLL cells is 
ubiquitin/proteasome–dependent. 
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 We also investigated whether the Bax degradation seen with TRAIL treatment in cell 
lines, and the reversal of this with Bortezomib, occurred in primary malignant B cells. Fresh 
CLL cells treated with 500 ng/ml soluble TRAIL were also found to have reduced Bax protein 
levels (Figure 7 A). TRAIL-induced Bax conformational change and apoptosis were low in the 
CLL cells (Figure 7 B and C). 10 nmol/L Bortezomib alone did not show significant effects on 
cell viability in CLL cells. However, Bortezomib and TRAIL in combination had a synergistic 
effect on apoptosis induction and Bax activation, with prevention of TRAIL-induced Bax 
degradation. As with the cell lines, Bax mRNA expression in primary CLL cells was not 
affected during TRAIL-mediated reduction in Bax protein expression or its reversal with 
Bortezomib (data not shown). 
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Discussion 
In this study, we demonstrate that Bax is a short-lived protein in malignant B-cells. Bax 
degradation occurs at the mitochondrial level probably prior to its stable mitochondrial 
membrane insertion. This affects the sensitivity of malignant B-cells to TRAIL-induced 
apoptosis. The proteasome inhibitor, Bortezomib, stabilizes Bax and enhances the pro-apoptotic 
activity of the Bax protein. Bortezomib alone, in appropriate concentrations, induces apoptosis 
in primary malignant B-cells by stabilizing Bax protein.   
The ubiquitin/proteasome-dependent degradation pathway is a major system for short-
lived protein degradation in eukaryotic cells.42 Many proteins must undergo subunit separation, 
local unfolding, or post-translational modification prior to recognition by the appropriate E3 
ubiquitin ligase.42,43 It was reported that Bax is a short-lived protein in tumor cells and its 
degradation is ubiquitin/proteasome dependent, due to an increased proteasome activity in tumor 
cells.1,4 The vexing problems are what is the trigger for Bax degradation and where is Bax 
degraded? The native Bax is a globular protein with a hydrophobic core center. In the resting 
state, it localizes in the cytosol or is loosely attached to the mitochondria in some models. Bax 
translocates to the mitochondrial outer membrane in the response to apoptotic signaling. The 
conformational changes in Bax enable its stable membrane insertion via the α5 - α6 helices and 
oligomerization with Bax and/or Bcl-2. However, Bax translocation to mitochondria does not 
commit cells to apoptosis, because Bax translocation and membrane insertion are separate 
events.15,44 In the experiments looking at Bax degradation in the mitochondria or cytosol, a 
detergent such as Triton X-100 was omitted because it can trigger Bax conformational change in 
a cell-free system.45 Bax protein is relatively stable in the cytosol in the absence of detergent. In 
the K562 mitochondria, Bax is in an inactive form and it requires the BH3-only protein for 
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triggering cytochrome c release.16,44 The mitochondrial Bax is vulnerable to degradation in the 
absence of the BH3-only protein tBid. The role of the BH3-only proteins on mitochondria is to 
promote Bax membrane insertion by engaging the multiple survival relatives guarding Bax and 
Bak.46 K562 cells have lower proteasome activity and this may be one of the reasons that 
K562 mitochondria maintain an abundant Bax protein. Having a higher proteasome 
activity, DHL-4 cytosol degrades K562 mitochondrial Bax rapidly in the absence of 
artificial ubiquitin. In the presence of ubiquitin, the K562 cytosol degrades mitochondrial 
Bax gradually and this is also inhibited by tBid. However, the sensitivity of Bax protein to 
degradation may depend on many factors, such as the specific conformation of Bax 
protein, less BH-3-only proteins, the cytosolic proteasome activity, the co-ordination of 
ubiquitin recognizing and conjugating with Bax. The general proteasome activity is not 
specific for Bax degradation.  
Using an antibody (6A7) to the active form of Bax, we detected Bax-ubiquitin 
conjugation after treatment with Bortezomib, suggesting that ubiquitin recognizes the 
active form of Bax. However, we could not rule out that ubiquitin may conjugate with the 
inactive Bax because none of the available antibodies that detect inactive Bax could be 
used for immuno-precipitation. We have recently observed (in another study) that the 
exposure of Bax hydrophobic domains during its conformational changes triggers ubiquitin 
recognition and the degradation process. The ubiquitin-sensitive domain of Bax is within its 
hydrophobic core (Yu et al, submitted). This also suggests that Bax translocation to 
mitochondria and subsequent conformational changes may be physical processes. This study 
shows that tBid or Bortezomib stabilize Bax and prevented mitochondrial Bax from 
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degradation, suggesting Bax degradation may occur prior to irreversible commitment to 
apoptosis.  
The protein levels of Bax are determined by two opposing forces: synthesis and 
degradation. Cancer cells lacking Bax protein are resistant to apoptosis. Therefore, blocking Bax 
degradation to increase Bax protein levels is an attractive target for anti-cancer therapy. Many 
anti-cancer reagents, such as DNA damaging agents, induce apoptosis by an increase in Bax 
expression and translocation,15 indicating that rapid synthesis can overwhelm Bax degradation 
activity. The effect of DNA damaging agents on Bax degradation activity is unknown. TRAIL 
induced Bax translocation and conformational change. However, rather than increased Bax 
expression, TRAIL treatment was associated with enhanced Bax degradation in resistant 
malignant B-cells.  It is known that tBid is required for TRAIL-induced Bax activation.47 Poor 
coordination between Bax mitochondrial translocation and the BH3-only proteins, such as tBid, 
or overexpression of Bcl-2 (a common feature of malignant B-cells), would leave mitochondrial 
Bax vulnerable to degradation.  Primary CLL cells were found to be inherently resistant to 
TRAIL22 and inhibition of Bcl-2 sensitized TRAIL-induced apoptosis in human leukemia and 
tumor cells.47,48 Although Bax is essential for TRAIL-induced apoptosis in certain cancer cells, 
the regulation of Bax in response to TRAIL is still elusive. We suggest that TRAIL-induced Bax 
degradation may be a consequence of insufficient levels of tBid or Bcl-2 overexpression, which 
cause a failure in mitochondrial membrane insertion. The proteasome inhibitor Bortezomib 
sensitized resistant cells to TRAIL-induced apoptosis by preventing Bax degradation and 
therefore maintaining levels of active Bax. These results suggest that proteasome-dependent Bax 
degradation is one of the mechanisms underlying the resistance of malignant B-cells to TRAIL-
induced apoptosis and that it can be prevented by co-treatment with a proteasome inhibitor.  
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Increased degradation activity of pro-apoptotic proteins may contribute to the 
development of cancer, as well as resistance of cancer cells to treatment. The human leukemia 
CLL is currently incurable, with frequent over-expression of Bcl-2 being one of the major 
causes of resistance of CLL cells to therapy. Furthermore, insufficient levels of Bax protein 
have also been reported to be a resistance factor in CLL in response to a variety of therapies.3, 
49,50 Reduced Bax protein expression was observed in several malignant B-cell lines, but this 
may not necessarily represent increased Bax degradation activity. Low Bax protein levels could 
also be due to a change in the balance between synthesis and degradation, namely, decreased 
synthesis combined with increased degradation activity.  
Bortezomib induces apoptosis in CLL cells in vitro.51,52 We found there was no 
correlation between Bax degradation activity and the sensitivity of CLL cells to Bortezomib-
induced apoptosis. Bortezomib caused Bax accumulation, a conformational change, 
translocation to mitochondria and oligomerization in CLL cells. Increased levels of NOXA 
protein were also observed when CLL cells were treated with Bortezomib. Bax up-regulation 
was also seen when CLL cells were treated with both Bortezomib and anti-CD20 antibody,53 
while co-treatment of CLL cells with Bortezomib plus cladribine and fludarabine induced an up-
regulation of tBid, another short-lived pro-apoptotic protein.54 It was reported that Bortezomib-
induced apoptosis was significantly decreased in Bax-knockout colon cancer cells.55 We 
propose that Bax accumulation and activation play an important role in Bortezomib -induced 
apoptosis.  
 Our results may have clinical application since inducible resistance to apoptosis occurs 
during TRAIL treatment and the combination of a proteasome inhibitor with TRAIL overcomes 
resistance to TRAIL by blocking Bax degradation. Further studies will focus on whether Bax 
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degradation is associated with clinical prognosis and outcome of patients with lymphoma and 
leukemia.  
Acknowledgements: We are thankful to Millennium Pharmaceutical Corporation for the 
generous supply of Bortezomib.  We are grateful for helpful advice from Professor Gerald 
Cohen and Dr. Stephen M Kelsey during this study. We thank Drs. J. Fitzgibbon and SJ Strauss 
for kindly providing the HRC, DoHH2, CRL and DHL-4 cell lines.  
 19
Reference 
1. Li B, and Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: 
involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000; 97:3850-
3855. 
2. Miyashita T, Kitada S, Krajewski S, et al.  Overexpression of the Bcl-2 protein increases the 
half-life of p21Bax. J Biol Chem. 1995;270:26049-26052. 
3. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic 
leukemia is determined by endogenous endonuclease content and relative expression of 
BCL-2 and BAX. J Immunol. 1996;156:2624-2630. 
4. Chang, YC, Lee, YS, Tejima, T, et al. mdm2 and bax, downstream mediators of the p53 
response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 
1998;9:79-84. 
5. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2-related multidomain 
proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 
2006;126:1366-1371. 
6. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein 
encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 
1990;63:1129-1136. 
7. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic 
active form of bid. A functional consequence on apoptosis induction. J Biol Chem. 
2000;275:21648-21652. 
8. Lotan R, Rotem A, Gonen H, et al.  Regulation of the proapoptotic ARTS protein by 
ubiquitin-mediated degradation. J Biol Chem. 2005;280:25802-25810.  
9. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome 
inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS 
and Noxa activation independent of p53 status. Blood. 2006;107:257-264. 
 20
10. Kuroda J, Puthalakath H, Cragg,MS, et al. Bim and Bad mediate imatinib-induced killing of 
Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. 
Proc Natl Acad Sci USA. 2006;103:14907-14912. 
11. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 
expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 
1996; 69:114-119. 
12. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to 
etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. 
Cancer Res. 1996;56:1834-1841. 
13. Schmitt E, Steyaert A, Cimoli G, Bertrand R. Bax-alpha promotes apoptosis induced by 
cancer chemotherapy and accelerates the activation of caspase 3-like cysteine proteases in 
p53 double mutant B lymphoma Namalwa cells. Cell Death Differ. 1998;5:506-516. 
14. Nishii K, Gibbons DL, Titley I, Papworth D, Goodhead DT, Greaves M. Regulation of the 
apoptotic response to radiation damage in B cell development. Cell Death Differ. 1998;5:77-
86. 
15. Jia L, Patwari Y, Srinivasula SM, Newland AC, Alnemri ES, Kelsey SM. Bax translocation 
is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene. 
2001;20:4817-4826. 
16. Liu FT, Goff LK, Hao JH, Newland AC, Jia L. Increase in the ratio of mitochondrial 
Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apoptosis. 
2004;9:377-384. 
17. Dewson G, Snowden R. Almond J, Dyer MJ, Cohen GM. Conformational change and 
mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of 
chronic lymphocytic leukemic cells. Oncogene. 2003;22:2643-2654. 
18. Chitambar CR, Wereley JP, Matsuyama S. Gallium-induced cell death in lymphoma: role of 
transferrin receptor cycling, involvement of Bax and the mitochondria, and effects of 
proteasome inhibition. Mol Cancer Ther. 2006;5:2834-2843. 
 21
19. Sutheesophon K, Kobayashi Y, Takatoku MA, et al. Histone deacetylase inhibitor 
depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial 
translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta 
Haematol. 2006;115:78-90. 
20. Pigneux A, Mahon FX, Moreau-Gaudry F, et al. Proteasome Inhibition Specifically 
Sensitizes Leukemic Cells to Anthracyclin-Induced Apoptosis through the Accumulation of 
Bim and Bax Pro-Apoptotic Proteins. Cancer Biol. Ther. 2007;6: [Epub ahead of print] 
21. MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced 
apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene. 2002;21:6809–6818. 
22. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of Histone Deacetylase Class I but not 
Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related 
Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Res. 2006 ;66:6785-6792. 
23. Hao XS, Hao JH, Liu FT, Newland AC, Jia L. Potential mechanisms of leukemia cell 
resistance to TRAIL-induced apoptosis. Apoptosis. 2003;8:601-607. 
24. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of 
bortezomib. Oncology (Williston Park). 2004; 18(14 Suppl 11):14-21.  
25. Shah SA, Potter MW, McDade TP, et al.  26S proteasome inhibition induces apoptosis and 
limits growth of human pancreatic cancer. J Cell Biochem. 2001;82:110-122.  
26. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple 
myeloma. J Biol Chem. 2002;277:16639-16647.  
27. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib 
abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-
dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 
2005;65:4902-4908. 
28. Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis 
in melanoma and myeloma cells. Cancer Res. 2005;65:6282-6293. 
 22
29. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic 
pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic 
leukemia cells. Apoptosis. 2006;11:1175-1193. 
30. Mitsiades CS, Treon SP, Mitsiades N, et al. TRAIL/Apo2L ligand selectively induces 
apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. 
Blood. 2001;98:795-804. 
31. Sayers TJ, Brooks AD, Koh CY, et al.  The proteasome inhibitor PS-341 sensitizes 
neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 
2003;102:303-310. 
32. Johnson TR, Stone K, Nikrad M, et al.  The proteasome inhibitor PS-341 overcomes TRAIL 
resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 
2003;22:4953-4963. 
33. Brooks AD, Ramirez T, Toh U, et al.  The proteasome inhibitor bortezomib (Velcade) 
sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann N Y Acad Sci. 
2005;1059:160-167. 
34. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome 
inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only 
proteins Bik and Bim. Mol Cancer Ther. 2005;4:443-449. 
35. Lundqvist A, Abrams SI, Schrump DS, et al.  Bortezomib and depsipeptide sensitize tumors 
to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate 
natural killer cell tumor cytotoxicity. Cancer Res. 2006;66:7317-7325.  
36. Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol ester-induced, cell-
cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst. 1990; 
82:501-509. 
37. Kluin-Nelemans HC, Limpens J, Meerabux J, et al. A new non-Hodgkin's B-cell line 
(DoHH2) with a chromosomal translocation t(14;18)(q32;q21). Leukemia. 1991;5:221-224. 
 23
38. Strauss SJ, Higginbottom K, Juliger S. The proteasome inhibitor bortezomib acts 
independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-
cell lymphoma cell lines. Cancer Res. 2007;67:2783-2790.  
39. Jia L, Macey MG, Yin Y, Newland AC, Kelsey SM. Subcellular distribution and 
redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood. 
1999;93:2353-2359. 
40. Liu FT, Newland AC, Jia L. Bax conformational change is a crucial step for PUMA-
mediated apoptosis in human leukemia. Biochem Biophys Res Commun. 2003;310:956-962. 
41. Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, Belka C. Type I and type II 
reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene. 
2005;24:130-140. 
42. Jia L, Patwari Y, Kelsey SM, Newland AC.  Trail-induced apoptosis in Type I leukemic 
cells is not enhanced by overexpression of Bax. Biochem Biophys Res Commun. 2001; 
283:1037-1045. 
43. Dohmen J. Chapter 12: Primary destruction signals. Proteasomes: The world of regulatory 
proteolysis. Wolfgang Hilt and Dieter H. Wolf. 2000; pp186-203. 
44. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 
1998;17:7151-7160. 
45. Upton JP, Valentijn AJ, Zhang L, Gilmore AP. The N-terminal conformation of Bax 
regulates cell commitment to apoptosis. Cell Death Differ. 2007;14:932-942  
46. Hsu YT, Youle RJ. Bax in murine thymus is a soluble monomeric protein that displays 
differential detergent-induced conformations. J Biol Chem. 1998 ;273:10777-10783. 
47. Willis SN, Fletcher JI, Kaufmann T, et al. Apoptosis initiated when BH3 ligands engage 
multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315:85685-85689. 
48. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G, Brady HJ. Mcl-1 interacts with truncated 
Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated 
apoptosis. J Biol Chem. 2006;281:5750-5759.  
 24
49. Hao JH, Yu M, Liu FT, Newland AC, Jia L. Bcl-2 inhibitors sensitize tumor necrosis factor-
related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial 
respiration in human leukemic CEM cells. Cancer Res. 2004;64:3607-3616. 
50. Fandy TE, Srivastava, R.K. Trichostatin A sensitizes TRAIL-resistant myeloma cells by 
downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol. 
2006;58:471-477.  
51. Bosanquet AG, Sturm I, Wieder T, et al. Bax expression correlates with cellular drug 
sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, 
cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia. 
2002;16:1035-1044. 
52. Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and 
Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell 
chronic lymphocytic leukemia. Am J Hematol. 2004;75:22-33. 
53. Pahler JC, Ruiz S, Niemer I, et al.  Effects of the proteasome inhibitor, bortezomib, on 
apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. 
Clin. Cancer Res. 2003;9:4570-4577. 
54. Kelley TW, Alkan S, Srkalovic G, Hsi ED. Treatment of human chronic lymphocytic 
leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. Leuk Res. 
2004; 28:845-850. 
55. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic effect of bortezomib in 
combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic 
leukemia cells. Leuk Res. 2006;30:1521-1529.  
56. Duechler M, Linke A, Cebula B, et al.  In vitro cytotoxic effect of proteasome inhibitor 
bortezomib in combination with purine nucleoside analogues on chronic lymphocytic 
leukaemia cells. Eur J Haematol. 2005;74:407-417. 
57. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response to the proteasome 
inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer 
cells. Cancer Biol Ther. 2003;2:694-699. 
 25
Figure legends 
Figure 1. Bax protein instability 
(A) Expression of Bcl-2, Bcl-XL, Bak and Bax proteins. 25 μg proteins/each lane were loaded 
to 12% SDS-PAGE. The anti-Bcl-2 (100) and anti-Bcl-XL antibody were used at 1:200 dilution; 
anti-Bax (2D2) antibody was used at 1:1000 dilution; anti-Bak antibody was used at 1:200 
dilution; and anti-β-actin antibody was used at 1:10,000 dilution. (B) RT-PCR detection of Bax 
mRNA levels.  (C) The lifespan of Bax protein. HRC, CRL or DoHH2 cell lines were pre-
incubated with or without 50 nmol/L Bortezomib for 2 hours and then treated with 50 
μg/ml CHX for 3 hours. Proteins were extracted hourly. Bax levels were evaluated by Western 
blotting using Bax 2D2 antibody at 1:1000 dilution. β-actin antibody was used at 1:10,000 
dilution. Numbers under each pairs of blots are the ratio of Bax/β-actin.  
Figure 2. Effect of TRAIL-induced Bax regulation.  
(A) TRAIL-induced apoptosis was assessed with the Annexin V assay using flow cytometry. 
Data shown are mean ± SD from three independent experiments. (B) Proteins were extracted 
from HRC, CRL or DoHH2 cells, which were treated with TRAIL for up to 24 hours.  
Figure 3. Bortezomib-induced Bax protein accumulation in DHL-4 cells.  
DHL-4 cells were treated with 100 nmol/L Bortezomib for 24 hours. Cells were collected for 
protein and mRNA extraction. (A) Bax protein expression was determined with Western 
blotting. Anti-Bax antibody, 2D2 was used at 1:1000 dilution. Anti-β-actin antibody was used at 
1:10,000 dilution. (B) Bax or actin mRNA was determined by RT-PCR. (C) TRAIL and 
Bortezomib-induced apoptosis in the DHL-4 cell line. After DHL-4 cells were incubated with or 
without 100 nmol/L Bortezomib for 24 hours, cells were incubated with (B+T) or without 500 
ng/ml TRAIL (Borte) for another 24 hours. Significantly increased sensitivity (P<0.0001, t-test) 
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of cells treated with Bortezomib and TRAIL was seen compared with cells treated with 
Bortezomib or TRAIL alone. 
Figure 4.  Prevention of Bax degradation by tBid at the mitochondrial level. 
(A) Determination of proteasome activity.  (A1) Proteasome activity was measured in both 
cytosol and mitochondrial fractions in the absence of ubiquitin. ‘Cyto’ and ‘Mito’ indicate 
cytosol and mitochondrion. ‘*’ indicates significantly different proteasome activities 
(P<0.0001) between DHL-4 and K562.  (A2) Inhibition of proteasome activity by 
Bortezomib.  Bortezomib (70 nmol/L) was added to the cytosol (5 μg/μl protein) one hour 
prior to the reaction. Data shown were from three separate experiments. ‘*’ indicates 
significant inhibition (P<0.0001, t-test). (B) Mitochondrial Bax degradation in K562 
cytosol. K562 mitochondria were incubated with K562 cytosol in the presence of ubiquitin. 
Mitochondria were mixed with cytosol according to a protein ratio of mitochondria/cytosol of 
1:2 and incubated at 30ºC for 3 hours. Bax degradation was monitored in the presence or 
absence of 10 nmol/L tBid. Bax protein levels were detected by Western blotting for both 
mitochondria and cytosol. (C) K562 mitochondria were either incubated in the 
degradation buffer containing ubiquitin or in the K562 cytosol without ubiquitin for 3 
hours. Bax protein levels were examined in the mitochondrial fraction. (D) Mitochondrial 
Bax degradation in the DHL-4 cytosol. Mitochondria were isolated from the K562 cells. Cytosol 
was extracted from DHL-4 cells. In this assay, ubiquitin were omitted in order to test if the 
DHL-4 cytosol has a higher Bax degradation activity. Mitochondria were mixed with cytosol 
according to a protein ratio of mitochondria/cytosol of 1:2 and incubated at 30ºC for up to 60 
minutes in the presence or absence of 10 nmol/L tBid. Bax protein levels were detected by 
Western blotting for both mitochondria and cytosol. (E) Bortezomib prevents Bax 
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degradation. DHL-4 cells were treated with 100 nmol/L Bortezomib for 24 hours and its 
cytosol was mixed with K562 mitochondria and incubated at 30°C for 5 hours. 
Mitochondrial Bax levels were then determined by Western blotting after separation from 
cytosol. Bax antibody (clone 2D2) was used for the Western blotting.  
Figure 5. Bortezomib-induced apoptosis and Bax activation in CLL cells.  
(A) Bortezomib-induced apoptosis in 10 CLL samples. Fresh CLL cells were treated with 
different concentrations of Bortezomib for 16 hours. Apoptotic cells were determined by the 
Annexin V assay. (B) Bortezomib (Borte)-induced Bax protein accumulation in 9 cases of CLL 
patients, (C) Bortezomib (Borte)-induced Bax protein accumulation, oligomerization and 
activation in 1 case of CLL patient. CLL cells were treated with Bortezomib for 16 hours. 
Accumulation of Bax protein was determined by Western blotting using the anti-Bax antibody, 
clone 2D2 at 1:1000 dilution. 30 μg protein was loaded into each lane. Bax dimers and trimers 
are shown in the top panel blot indicated by 2× and 3×. For detection of conformationally 
changed Bax, the active form of Bax was immuno-precipitated (IP) by Bax 6A7 antibody and 
probed by Bax 2D2 antibody. (D) Bax translocation to mitochondria. CLL cells were treated 
with or without 20 nmol/L Bortezomib for 16 hours. Cells were stained with 100 nmol/L 
MitoTracker for 15 minutes, washed for 3 times, then fixed and permeabilized. Slides were 
stained with anti-Bax clone 3 antibody (1:20 dilution) for 1 hour and then stained with FITC-
conjugated anti-mouse IgG (1:50 dilution) for 1 hour. Finally, slides were stained with 50 ng/ml 
DAPI. The red color indicates the mitochondrial location and the yellow color represents the 
active Bax in the mitochondria.  
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Figure 6. Bortezomib-induced poly-ubiquitination and Bax-ubiquitin conjugation.  
Fresh CLL cells were treated with Bortezomib for 16 hours. (A) Poly-ubiquitination. CLL cells 
from 3 different patients were lysed with the lysis buffer. 50 μg proteins were loaded into each 
lane. The anti-ubiquitin antibody was used at 1:500 dilution. Multiple ladders in the blot show 
an accumulation of poly-ubiquitinated proteins. (B) CLL cells were lysed with Chaps containing 
lysis buffer. 500 μg protein was used for immuno-precipitation with Bax 6A7 antibody 
overnight at 4°C and Bax-ubiquitin conjugation was probed with the anti-ubiquitin antibody at 
1:500 dilution. The numbers on the left side of the blot are molecular weights of standard 
proteins.  
Figure 7. Proteasome inhibitor facilitates TRAIL-induced Bax activation and apoptosis. 
Fresh CLL cells were pre-treated with 10 nmol/L Bortezomib for 1 hour and then incubated 
with or without 500 ng/ml TRAIL, for 16 hours. (A) TRAIL -/+ Bortezomib induced changes 
of Bax protein levels in 7 cases of CLL patients. (B) Association between Bax protein levels 
and Bax conformational change. ‘CLL’ indicates the control; ‘T’, TRAIL-treated; ‘B’, 
Bortezomib-treated; and ‘B+T’, treated with Bortezomib and TRAIL. The anti-Bax antibody 
2D2 was used for Western blotting. The active Bax proteins were immuno-precipitated with 1 
μg anti-Bax 6A7 antibody and detected by Western blotting using anti-Bax 2D2 antibody at 
1:1000 dilution. (C) Apoptotic cell death was measured by DNA content assay. This is a one of 
three separate experiments. Numbers shown in the flow cytometry profiles are percentages of 
apoptotic cells (sub-G0/G1 population).   
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